The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending the use in the Cancer Drugs Fund (CDF) of GlaxoSmithKline’s Jemperli (dostarlimab) as a second-line treatment for endometrial cancer with high microsatellite instability or mismatch repair deficiency. The CDF allows patients to access a new treatment while further data is collected on its clinical and cost-effectiveness, to enable NICE to make a final recommendation on its routine use in the national health service (NHS) in England.
NICE estimates that 124 patients a year will be eligible to receive dostarlimab through the NHS in England.
Blake Dark, Director for NHS England’s Commercial Medicines Directorate commented, “This is another example of where the Cancer Drugs Fund (CDF) is able to fast-track the most clinically promising treatment to patients whilst further data is collected to ensure the NHS pays a price that is fair to the taxpayer.
“Dostarlimab is the 94th drug to be funded via the CDF since 2016, joining treatments for over 200 different cancer indications. To date, we have over 75,000 patients registered to receive a CDF funding treatment, many of whom will receive treatment sooner than they previously would have done”.